Retatrutide showed substantial weight reductions in placebo-controlled obesity trials. Tirzepatide has its own randomized obesity studies, including SURMOUNT-1, with different populations and time points.
The direct trial is TRIUMPH-5
TRIUMPH-5 directly compares retatrutide with tirzepatide in adults with obesity. As of November 6, 2026, a head-to-head result was not found in the cited study record or sponsor materials.
| Intervention | Trial | Follow-up | Mean weight reduction | Context |
|---|---|---|---|---|
| Retatrutide | TRIUMPH-1 | 80 weeks | 28.3% vs 2.2% placebo | Sponsor efficacy analysis; 12 mg arm |
| Tirzepatide | SURMOUNT-1 | 72 weeks | 20.9% vs 3.1% placebo | 15 mg arm |
| Semaglutide | STEP 1 | 68 weeks | 14.9% vs 2.4% placebo | 2.4 mg arm |
These percentages come from separate trials. Their populations, study durations, analysis methods and placebo responses differ. In SURMOUNT-5, the direct tirzepatide and semaglutide comparison yielded 20.2% and 13.7% mean reductions, respectively, at 72 weeks.
How to interpret the evidence
The evidence establishes placebo-controlled effects for both molecules. A claim about which causes greater weight loss in a common population depends on the direct comparison.
Give the strongest weight to studies that randomized both treatments within a shared protocol for the clinical question you are asking.